Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Sells 11,447 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $7.95, for a total transaction of $91,003.65. Following the transaction, the director now owns 7,218,414 shares in the company, valued at $57,386,391.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, April 16th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.66, for a total value of $87,684.02.
• On Tuesday, April 2nd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.82, for a total value of $100,962.54.
• On Tuesday, March 19th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $10.79, for a total value of $216,382.66.
• On Tuesday, March 5th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $12.06, for a total value of $241,851.24.
• On Tuesday, February 20th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $12.32, for a total value of $247,065.28.
• On Tuesday, February 6th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.30, for a total value of $106,457.10.

Recursion Pharmaceuticals Price Performance

NASDAQ RXRX traded up $0.45 during trading hours on Thursday, hitting $8.79. The company’s stock had a trading volume of 3,792,689 shares, compared to its average volume of 6,395,401. Recursion Pharmaceuticals, Inc. has a 12 month low of $4.55 and a 12 month high of $16.75. The company’s 50 day simple moving average is $10.10 and its two-hundred day simple moving average is $9.16. The company has a market cap of $2.06 billion, a P/E ratio of -5.67 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. The company had revenue of $10.89 million during the quarter, compared to the consensus estimate of $12.37 million. As a group, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. ARK Investment Management LLC lifted its position in shares of Recursion Pharmaceuticals by 200.4% during the 4th quarter. ARK Investment Management LLC now owns 20,654,287 shares of the company’s stock valued at $203,651,000 after buying an additional 13,777,689 shares in the last quarter. Mubadala Investment Co PJSC purchased a new position in shares of Recursion Pharmaceuticals during the 4th quarter valued at about $128,041,000. FMR LLC lifted its position in shares of Recursion Pharmaceuticals by 134.4% during the 3rd quarter. FMR LLC now owns 10,689,532 shares of the company’s stock valued at $81,775,000 after buying an additional 6,129,935 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its position in shares of Recursion Pharmaceuticals by 161.2% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 9,203,780 shares of the company’s stock valued at $90,749,000 after buying an additional 5,680,656 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. lifted its position in shares of Recursion Pharmaceuticals by 161.2% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 9,203,780 shares of the company’s stock valued at $90,565,000 after buying an additional 5,680,656 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on RXRX shares. KeyCorp raised their price target on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Monday, March 4th. Needham & Company LLC restated a “buy” rating and set a $17.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, April 9th. Finally, TD Cowen started coverage on Recursion Pharmaceuticals in a report on Friday, January 26th. They set a “market perform” rating for the company. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, Recursion Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $12.75.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.